Whenever biopharmaceutical experts and policymakers discuss medical innovation, they seem to focus only on drug discovery and development and access.
The U.S. health care system has both advantages as well as shortcomings when compared to systems in other developed countries.
A common expression used when computing data is “garbage in, garbage out,” or GIGO. The term refers to the fact that computers operate logically; thus flawed or nonsensical input data produce nonsensical outputs or findings.
Will patients ever shop for health care the way consumers do for a new mobile phone?
Payments for health care services in the U.S. are under a great deal of scrutiny by policy makers, insurers, employers and patients.
One of the most under-appreciated and underutilized ways to reduce medical costs in the U.S. is health care prevention.
As the great Sen. Daniel Patrick Moynihan once said, “Everyone is entitled to his own opinion, but not to his own facts.” Finally, the facts, in the form of data released in several new studies and systematic analytical reviews, are undermining the narrative that drug costs have been the main driver of rising health care expenditures and insurance premiums.
No one disputes that addressing ever-increasing health care costs in the United States is an important societal and policy goal. The rise in out-of-pocket costs leaves patients and families vulnerable to significant financial hardship. Ultimately, the solution is to evaluate and reward the most cost-beneficial interventions in health care. Unfortunately, policymakers today are deluged with an array of incomplete or biased set of data points which may lead them to draw incorrect conclusions that could possibly hinder the development of biopharmaceutical cures of the future.
Information never stops. We help you start your day by making sense of it all. Over 150,000 government and industry executives rely on Morning Consult to stay informed. Our original reporting and morning email briefings make it possible for you to know everything you need to know, every day, at the intersection of Wall Street and business strategy, policy and politics.